Artificial Intelligence-Driven De Novo Peptide Drug Design: Architectures, Pipelines, and Translational Challenges
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
In peptide drug design, function often emerges from the conformational ensemble encoded by a sequence and from how that ensemble engages a target. From this perspective, de novo peptide design can be viewed as an inverse problem of the sequence–structure–function relationship: starting from predefined functional and pharmacological objectives, one infers the required structural constraints and interfacial features and then generates candidate sequences that satisfy them. Achieving this goal requires a deeper mechanistic understanding of how peptide conformational ensembles, molecular recognition, and functional determinants jointly govern activity, as well as the ability to encode these principles in computational representations and models that are amenable to learning, explicit constraint, and optimization. Recent advances in artificial intelligence (AI)-driven approaches, including protein language models (pLMs), diffusion and latent diffusion models (LDM), conditional flow matching (CFM), and AI-assisted prediction and screening, are beginning to shift the field beyond sequence or structure generation toward function-oriented and controllable peptide design. At the same time, these advances have highlighted persistent bottlenecks in sequence–structure co-generation, conformational control in flexible systems, and interpretable multi-objective optimization. As de novo peptide design methods rapidly proliferate, technical routes are diversifying and benchmarking standards remain fragmented. This review therefore surveys recent progress in AI-driven generative architectures, control strategies, and emerging directions, with the aim of distilling reusable principles and providing a structured reference for reliable, translationally relevant functional peptide design.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Artificial Intelligence-Driven De Novo Peptide Drug Design: Architectures, Pipelines, and Translational Challenges
- Date Crossref
- 01/08/2026
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.